Five Prime Therapeutics

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating Five Prime (NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen.

Ademi LLP alleges Five Prime’s financial outlook is excellent and yet Five Prime shareholders will receive only $38 per each share of Five Prime stock.  The merger agreement unreasonably limits competing bids for Five Prime by prohibiting solicitation of further bids, and imposing a termination penalty if Five Prime accepts a superior bid. Five Prime insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of Five Prime’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Five Prime.